2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 553

Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study
Abstract Number: 1742

Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multi-Ethnic Cohort
Abstract Number: 501

EULAR Definition of “Arthralgia Suspicious for Progression to Rheumatoid Arthritis” in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies
Abstract Number: 1094

EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases
Abstract Number: 170

Evaluating an Illustrated Storybook for Children with Juvenile Idiopathic Arthritis
Abstract Number: 225

Evaluating Fibromyalgia Symptoms in Transgender Patients
Abstract Number: 2242

Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis
Abstract Number: 1732

Evaluating the New 2018 ACR/EULAR SLE Classification in Pediatric Patients
Abstract Number: 1855

Evaluating the OMERACT Definitions of Ultrasound Gout Structural Lesions in the Diagnosis of Gout
Abstract Number: 288

Evaluating the Performance of a Single-site Musculoskeletal Ultrasound Clinic Associated with an Academic Rheumatology Practice: Diagnostic and Therapeutic Impact on Patient Care and Survey of Patient and Physician Satisfaction
Abstract Number: 160

Evaluation of ACGME Competencies in a Rheumatology Observed Structured Clinical Examination
Abstract Number: 1466

Evaluation of Changes in Oral Health-Related Quality of Life over Time in Patients with Sjögren’s Syndrome
Abstract Number: 2486

Evaluation of Clinical and Functional Parameters by Joint Involvement and Remission in Psoriatic Arthritis
Abstract Number: 1399

Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset
Abstract Number: 2213

Evaluation of Factors Associated with Bone Structure in an SLE Cohort Measured by Clinical 3T MRI and DEXA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].